Author: XSeed Capital

6P4A3821

XSeed Invests In Narrative, A Platform Connecting Buyers And Sellers Of Data

April 17, 2017

XSeed Capital is very excited to announce our investment in Narrative, a platform that enables buyers and sellers of raw data events to come together and transact.

As more people, more companies, and more devices connect over the Internet, the engagement and interactions of those constituents creates overwhelming amounts of data. At the same time, organizations are deploying

Read More
24500097123_61e012515f_k

XSeed Invests In FINDMINE, Bringing Critical Technology And Data Sets To Retailers

February 6, 2017

XSeed is very excited to announce our investment in FINDMINE, a software platform that automatically curates products and product groups for use across merchant’s ecommerce, digital marketing and in-store displays or applications. The company is bringing critical technology and new data sets to retailers, allowing them not only to apply common technical advancements across their omni-channel efforts,

Read More
xseed-032-Edit

SurveyMonkey’s Damon Cronkey Joins XSeed Capital

June 20, 2016

We at XSeed have been thinking a lot about the near future – not about the deep and disruptive social and economic impacts of ongoing innovations in autonomous and semi-autonomous systems, deep learning, bots and robots, VR and AR (all areas where we have been deploying capital for some time). Rather, we’ve been thinking about where the current economic

Read More
SharonGoldstein-7784

A Conversation With Former EIR Sharon Goldstein

January 27, 2016

One of XSeed’s recent Executives-in-Residence (EIR) and former portfolio executive, Sharon Goldstein, shared some insights about her career, her time at XSeed as an EIR and new position at ShipHawk.

Tell us a bit about you:

I’ve always been drawn to audacious opportunities with high barriers to entry. My first role out of business school was as

Read More
GEN_GeneWEAVE_4inch

GeneWEAVE Acquired By Roche

August 14, 2015

One of our goals at XSeed is to invest in entrepreneurs who pursue risky, paradigm changing ideas to solve big problems that seem intractable using established approaches. Rapid, cost-effective diagnosis and data-guided treatment of antibiotic resistant diseases is one such problem – causing about 25,000 deaths and over 2 million illnesses a year in the U.S. alone, with new,

Read More